Research and Clinical Trials

Title  
Lilly LZAX
Brief Description  
This study is to assess solanezumab, administered as an intravenous infusion at a dose of 400 mg every 4 weeks for 76 weeks, will slow the cognitive and functional decline of Alzheimer's disease as compared with placebo in patients with mild Alzheimer's disease.
Who may be Eligible  
Male or female with mild Alzheimer's disease.
Specialty/Disorder  
Alzheimer´s Disease
Start Date  
09/15/2013
IRB Number  
C-175
Principal Investigator  
Tcheremissine, Oleg
Contact Name  
Dineen

For More Information, Contact   Dineen  Gardner , BA
Phone:  (704) 446-7511  Fax:  (704) 446-7505 
Email:  dgardner@carolinas.org
Address:  465 N. Wendover Road
Charlotte, NC 28211
Close